Antibiotics Antineoplastic Clinical Trials

All Categories Medications / Interventions » Aa » Antibiotics Antineoplastic

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Conditions: Advanced Cancer; Solid Tumor
Interventions: Drug: Vemurafenib; Drug: Everolimus; Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012
PROMUS Element Plus US Post-Approval Study

Condition: Coronary Artery Disease
Interventions: Device: PROMUS Element Plus Coronary Stent System; Drug: Aspirin; Drug: P2Y12 antagonist
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Not yet recruiting - verified May 2012
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Condition: Lymphoma
Interventions: Drug: Romidepsin; Drug: Ifosfamide; Drug: Mesna; Drug: Carboplatin; Drug: Etoposide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Not yet recruiting - verified May 2012
Doxycycline, Temozolomide and Ipilimumab in Melanoma

Condition: Melanoma
Interventions: Drug: Doxycycline; Drug: Ipilimumab; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Vandetanib With Everolimus

Condition: Advanced Cancers
Interventions: Drug: Vandetanib; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Conditions: Carcinoma of the Appendix; Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery; Other: quality-of-life assessment; Drug: hyperthermic intraperitoneal chemotherapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2009
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis

Condition: Ankylosing Spondyloarthritis
Interventions: Drug: Apremilast tablet 20 mg; Drug: Apremilast tablet 30 mg BID; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer

Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Doxorubicin-EMCH
Sponsors: CytRx; CytRx
Not yet recruiting - verified May 2012
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction

Condition: Acute Myeloid Leukemia
Intervention: Drug: Lenalidomide
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Celgene Corporation
Not yet recruiting - verified April 2012
Maintenance Lenalidomide in Lymphoma

Condition: Lymphoma
Intervention: Drug: Lenalidomide
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified April 2012
Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Crohn's Allogeneic Transplant Study

Condition: Crohn's Disease
Interventions: Drug: cyclophosphamide; Radiation: total-body irradiation; Drug: mycophenolic acid enteric coated; Drug: tacrolimus; Other: quality-of-life assessment; Other: laboratory biomarker analysis; Drug: fludarabine phosphate; Procedure: allogeneic bone marrow transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center
Not yet recruiting - verified April 2012
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

Condition: CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions: Drug: Part 1, Cohort 1; Drug: Part 1, Cohort 2; Drug: Part 1, Cohort 3; Drug: Part 2, Cohort 1; Drug: Part 2, Cohort 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Not yet recruiting - verified May 2012
A Fixed−Sequence, Two−Period, Open−Label Drug−Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD−1211

Condition: Healthy
Interventions: Drug: TD-1211; Drug: TD-1211+ itraconazole
Sponsors: Theravance; Theravance
Not yet recruiting - verified March 2012
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast

Condition: Healthy
Interventions: Drug: Apremilast; Drug: Rifampin
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease

Conditions: Scleroderma, Systemic; Sclerosis, Systemic; Systemic Scleroderma; Systemic Sclerosis
Interventions: Drug: Pomalidomide (CC-4047); Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Not yet recruiting - verified April 2012
Intra-arterial Versus Intravenous Cisplatin, Combined With Radiation, for Oral Cavity and Oropharynx Cancer

Condition: Head and Neck Cancer
Interventions: Drug: Intra-arterial cisplatin; Drug: Intravenous cisplatin
Sponsors: Southern Illinois University; Southern Illinois University
Not yet recruiting - verified April 2012
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab

Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Valproic Acid; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Condition: Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Intervention: Drug: Everolimus (RAD001)
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified March 2012
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Intervention: Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Condition: Multiple Myeloma
Interventions: Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan); Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan); Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide); Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12); Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors: University of Iowa; University of Iowa; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma

Condition: Recurrent Glioma
Interventions: Drug: Bevacizumab; Drug: Minocycline; Radiation: Radiation
Sponsors: University of Utah; University of Utah
Not yet recruiting - verified April 2012
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

Condition: AL Amyloidosis
Interventions: Drug: Pomalidomide; Drug: Dexamthasone
Sponsors: Boston Medical Center; Boston Medical Center; Celgene Corporation
Not yet recruiting - verified February 2012
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

Conditions: Recurrent/Refractory CNS; Intraocular Lymphoma
Interventions: Drug: Lenalidomide; Drug: Rituximab
Sponsors: University of California, San Francisco; James Rubenstein; University of California, San Francisco; Celgene Corporation; Genentech
Not yet recruiting - verified March 2012
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Pegylated Liposomal Doxorubicin (PLD); Drug: Dexamethasone
Sponsors: Oncotherapeutics; Oncotherapeutics; Celgene Corporation
Recruiting - verified February 2012
Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Texas Tech University Health Sciences Center
Not yet recruiting - verified January 2012
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Conditions: Breast Cancer; Obesity
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; University of Texas
Recruiting - verified April 2012
Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: vismodegib; Drug: sirolimus; Procedure: positron emission tomography; Procedure: computed tomography; Other: pharmacological study; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: tacrolimus; Biological: rituximab; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; Genentech
Not yet recruiting - verified March 2012
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Other: pharmacological study; Drug: tacrolimus; Drug: sirolimus; Biological: anti-thymocyte globulin; Drug: fludarabine phosphate; Drug: busulfan; Drug: bortezomib; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: Dexamethasone; Drug: Clarithromycin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Lenalidomide
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Onyx Therapeutics, Inc.
Not yet recruiting - verified March 2012
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma

Condition: Melanoma
Interventions: Biological: dactinomycin; Drug: melphalan; Biological: Conditionally replicative adenovirus 3/5-delta
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified February 2012
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Adriamycin, vinblastine, and dacarbazine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Seattle Genetics, Inc.
Recruiting - verified April 2012
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Aplastic Anemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Congenital Amegakaryocytic Thrombocytopenia; Diamond-Blackfan Anemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Paroxysmal Nocturnal Hemoglobinuria; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Severe Combined Immunodeficiency; Severe Congenital Neutropenia; Shwachman-Diamond Syndrome; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia; Wiskott-Aldrich Syndrome
Interventions: Drug: fludarabine phosphate; Drug: melphalan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Conditions: Hematologic Malignancy; Leukemia; Acute Lymphoblastic Leukemia; ALL; Acute Myelogenous Leukemia; AML; Chronic Lymphocytic Leukemia; CLL; Lymphoma; Hodgkin's Lymphoma; Non-hodgkin's Lymphoma; Myeloma
Interventions: Radiation: Total Body Irradiation (TBI); Biological: Donor Lymphocyte Infusion (DLI); Drug: Cyclophosphamide (CY); Drug: Tacrolimus; Drug: Mycophenolate Mofetil (MMF); Biological: Hematopoietic Stem Cell Transplant (HSCT)
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012
Temsirolimus as Second-line Therapy in HCC

Condition: Unresectable or Metastatic Hepatocellular Carcinoma
Intervention: Drug: Temsirolimus
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified March 2012
Topical Rapamycin to Erase Angiofibromas in TSC

Conditions: Angiofibromas; Tuberous Sclerosis
Interventions: Drug: Placebo; Drug: Rapamycin; Drug: Rapamycin
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston
Recruiting - verified May 2012
Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Everolimus; Drug: Prednisone; Drug: Vincristine; Drug: PEG-Asparaginase; Drug: Doxorubicin; Drug: Dexrazoxane
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Novartis
Recruiting - verified January 2012
Atorvastatin Calcium-Treated Donor Peripheral Blood Stem Cell Transplant in Preventing Severe Graft-Versus-Host Disease in Patients With Hematological Malignancies

Conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Previously Treated Myelodysplastic Syndromes; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: atorvastatin calcium; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
Study of Mitomycin-C Application in Laryngotracheal Stenosis

Conditions: Laryngeal Stenosis; Subglottic Stenosis; Tracheal Stenosis
Interventions: Drug: Mitomycin -C; Other: Saline application
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified January 2012
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Conditions: Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Osteosarcoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Prostate Cancer; Recurrent Rectal Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Small Intestine Leiomyosarcoma; Stage I Colon Cancer; Stage I Rectal Cancer; Stage I Uterine Sarcoma; Stage IA Breast Cancer; Stage IA Gastric Cancer; Stage IA Ovarian Epithelial Cancer; Stage IA Ovarian Germ Cell Tumor; Stage IB Breast Cancer; Stage IB Gastric Cancer; Stage IB Ovarian Epithelial Cancer; Stage IB Ovarian Germ Cell Tumor; Stage IC Ovarian Epithelial Cancer; Stage IC Ovarian Germ Cell Tumor; Stage II Breast Cancer; Stage II Uterine Sarcoma; Stage IIA Colon Cancer; Stage IIA Gastric Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Rectal Cancer; Stage IIB Colon Cancer; Stage IIB Esophageal Cancer; Stage IIB Gastric Cancer; Stage IIB Melanoma; Stage IIB Non-small Cell Lung Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Rectal Cancer; Stage IIC Colon Cancer; Stage IIC Melanoma; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Rectal Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Esophageal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Melanoma; Stage IIIA Non-small Cell Lung Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Rectal Cancer; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Esophageal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Melanoma; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Rectal Cancer; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Esophageal Cancer; Stage IIIC Gastric Cancer; Stage IIIC Melanoma; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Rectal Cancer; Stage IV Bladder Cancer; Stage IV Esophageal Cancer; Stage IV Gastric Cancer; Stage IV Melanoma; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Sirolimus Injections for Autoimmune Scleritis

Condition: Scleritis
Intervention: Drug: Sirolimus
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified December 2011
Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

Condition: Anemia, Sickle Cell
Intervention: Drug: pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified January 2012
Phase II Study of Alternating Sunitinib and Temsirolimus

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Temsirolimus
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified January 2012
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: dalteparin; Drug: lenalidomide; Drug: dexamethasone; Other: laboratory biomarker analysis
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified January 2012
Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma

Conditions: Histological Evidence of Metastatic Clear Cell Renal Cell Carcinoma; That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens; With Evidence of Progressive Disease on or Within 6 Months; of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous; Therapy With Bevacizumab, IL2, or Interferon Are Permitted.
Interventions: Drug: Hydroxychloroquine; Drug: RAD001
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma

Conditions: Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Interventions: Drug: INNO-206; Drug: Doxorubicin
Sponsors: CytRx; CytRx
Recruiting - verified March 2012
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

Condition: Cancer
Interventions: Drug: BEZ235; Drug: Everolimus
Sponsors: University of Cincinnati; University of Cincinnati; Novartis
Recruiting - verified January 2012
ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: ACE-011; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified May 2012
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions: Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Drug: sirolimus; Other: laboratory biomarker analysis; Biological: sargramostim
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2012
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)

Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Pomalidomide; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation; Multiple Myeloma Research Consortium
Recruiting - verified April 2012
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL)

Conditions: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012
Study of How Well Letrozole Works in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer

Conditions: Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis
Interventions: Drug: letrozole; Drug: lapatinib; Drug: everolimus
Sponsors: University of Maryland; University of Maryland; Novartis Pharmaceuticals; GlaxoSmithKline
Not yet recruiting - verified December 2011
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone; Drug: Ofatumumab; Drug: Lenalidomide; Drug: Sargramostim
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; GlaxoSmithKline; Celgene Corporation
Recruiting - verified January 2012
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012
Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Condition: Sarcoma, Kaposi
Intervention: Drug: Pomalidomide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Conditions: Leukemia; Lymphoma
Interventions: Drug: Rituximab; Drug: 111In Ibritumumab; Procedure: Planar Scintigraphy Imaging; Drug: 90Y IbritumumabTiuxetan; Drug: Fludarabine; Drug: Bendamustine; Drug: Thymoglobulin; Drug: Tacrolimus; Drug: Methotrexate; Drug: Mycophenolate; Drug: G-CSF; Procedure: Stem Cell Transplantation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Spectrum Pharmaceuticals, Inc
Not yet recruiting - verified May 2012
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Not yet recruiting - verified March 2012
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus; Drug: Pasireotide
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012
Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Interventions: Drug: Drug-Eluting Beads with Doxorubicin; Drug: Lipiodol ethanol mixture
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Conditions: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Alisertib; Drug: Pralatrexate; Drug: Romidepsin; Drug: Gemcitabine
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: Loyola University; Loyola University
Recruiting - verified December 2011
Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Condition: Sickle Cell Disease
Interventions: Procedure: Allogeneic Non-Myeloablative Stem Cell Transplantation; Drug: Alemtuzumab; Drug: Sirolimus
Sponsors: University of Illinois; University of Illinois
Recruiting - verified November 2011
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention

Conditions: Allogeneic Blood and Marrow Transplantation (BMT); Graft Versus Host Disease
Intervention: Drug: Mycophenolate mofetil
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified December 2011
Study of Axitinib and Temsirolimus in Solid Tumors

Condition: Cancer
Interventions: Drug: Axitinib; Drug: Temsirolimus
Sponsors: Emory University; Emory University
Recruiting - verified March 2012
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Condition: Follicular Lymphoma
Interventions: Drug: Rituximab; Drug: Lenalidomide; Drug: Rituximab-CHOP; Drug: Rituximab-CVP; Drug: Rituximab-Bendamustine
Sponsors: Celgene Corporation; Celgene Corporation; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012
Cord Blood Fucosylation

Conditions: Blood And Marrow Transplantation; Leukemia; Lymphoma; Transplantation Infection; Transplantation, Bone Marrow
Interventions: Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Mycophenolate mofetil; Drug: Tacrolimus; Procedure: Cord Blood Infusion; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified April 2012
Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Conditions: Macular Edema; Cystoid Macular Edema; Uveal Melanoma; Radiation Maculopathy; Radiation Retinopathy
Intervention: Drug: Ozurdex (Dexamethasone intravitreal implant )
Sponsors: Wills Eye; Arman Mashayekhi; Allergan
Not yet recruiting - verified November 2011
Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)

Condition: Colon Cancer Liver Metastasis
Interventions: Drug: Lyso-Thermosensitive Liposomal Doxorubicin; Other: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified March 2012
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)

Conditions: Idiopathic Pulmonary Fibrosis; Diffuse Parenchymal Lung Disease; Interstitial Lung Disease
Interventions: Drug: sirolimus; Other: Placebo
Sponsors: University of Virginia; University of Virginia; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 2012
Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Conditions: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma
Intervention: Biological: Toca 511
Sponsors: Tocagen Inc.; Tocagen Inc.
Recruiting - verified January 2012
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia; Advanced Myelodysplastic Syndrome
Interventions: Drug: Panobinostat; Drug: Cytarabine; Drug: Daunorubicin
Sponsors: University of California, San Francisco; C. Babis Andreadis; University of California, San Francisco; Novartis
Recruiting - verified March 2012
Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

Conditions: Esophageal Cancer; Neoplasms, Esophageal
Interventions: Drug: Everolimus; Drug: Paclitaxel; Drug: carboplatin; Drug: cetuximab
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified March 2012
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Condition: Solid Tumors
Intervention: Drug: BKM120 and RAD001
Sponsors: Emory University; Emory University; Novartis Pharmaceuticals
Recruiting - verified February 2012
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance After Autologous Stem Cell Transplantation

Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center; State University of New York - Downstate Medical Center; NYU MEDICAL CENTER; University of Rochester; Weill Medical College of Cornell University; Stamford Hospital
Recruiting - verified March 2012
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Maintenance lenalidomide
Sponsors: Yale University; Yale University; Celgene Corporation
Recruiting - verified March 2012
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Drug: doxorubicin hydrochloride; Drug: vinblastine; Drug: dacarbazine; Procedure: quality-of-life assessment; Genetic: DNA analysis; Genetic: RNA analysis; Radiation: fludeoxyglucose F 18; Procedure: positron emission tomography; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymorphism analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified November 2011
A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; CORE Science Solutions; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified February 2012
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease

Condition: Graft Versus Host Disease
Interventions: Drug: Cyclophospahmide and Sirolimus; Drug: Low dose IL-2, Cyclophosphamide and Sirolimus; Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified October 2011
Pasireotide, Everolimus and Selective Internal Radioemobilization Therapy for Unresectable Hepatic Metastases

Condition: Neuroendocrine Tumors
Interventions: Drug: Pasireotide; Procedure: Sir Sphere Radioembolization; Drug: Everolimus
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified February 2012
Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast
Interventions: Drug: Eribulin; Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Emory University; Emory University; Eisai Inc.
Recruiting - verified December 2011
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Condition: Neoplasm Malignant
Interventions: Drug: Iniparib (SAR240550-BSI-201); Drug: Gemcitabine; Drug: Carboplatin; Drug: Placlitaxel; Drug: Pegylated liposomal doxorubicin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: panobinostat; Drug: lenalidomide
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Celgene Corporation; Novartis
Recruiting - verified February 2012
Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Sirolimus for Advanced Age-Related Macular Degeneration

Conditions: Age-Related Macular Degeneration; Bilateral Geographic Atrophy
Intervention: Drug: Sirolimus
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified August 2011
International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

Condition: Pleuropulmonary Blastoma
Interventions: Drug: Vincristine; Drug: Dactinomycin; Drug: Cyclophosphamide; Drug: Ifosfamide; Drug: Doxorubicin
Sponsors: Children's Hospitals and Clinics of Minnesota; Children's Hospitals and Clinics of Minnesota
Recruiting - verified November 2011
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma

Conditions: Mycosis Fungoides; Cutaneous T-Cell Lymphoma; Neoplasms
Intervention: Drug: Romidepsin (FR901228)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Conditions: Leukemia; Lymphoma
Interventions: Drug: Rituximab; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified December 2011
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Intervention: Drug: RAD001 + BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Gemcitabine, Cisplatin, and Lenalidomide for Bladder Cancer

Conditions: Ureteral Neoplasms; Urinary Bladder Neoplasms; Urethral Neoplasms
Interventions: Drug: Lenalidomide; Drug: Cisplatin; Drug: Gemcitabine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Azacitidine + Lenalidomide Combo in the Elderly Previously Treated Acute Myeloid Leukemia (AML) & High-Risk Myelodysplastic Syndromes (MDS)

Conditions: Leukemia; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
Interventions: Drug: Azacitidine; Drug: Lenalidomide
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified September 2011
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: TH-302 in Combination with Doxorubicin; Drug: Doxorubicin
Sponsors: Threshold Pharmaceuticals; Threshold Pharmaceuticals; Sarcoma Alliance for Research through Collaboration (SARC)
Recruiting - verified March 2012
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: Everolimus; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Novartis
Not yet recruiting - verified February 2012
Comparative Study of the Safety and Effectiveness of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

Condition: Glaucoma
Interventions: Device: Use of ologen Collagen Matrix in trabeculectomy (ologen); Drug: Use of Mitomycin-C (MMC) in trabeculectomy
Sponsors: Aeon Astron Europe B.V.; Aeon Astron Europe B.V.
Recruiting - verified January 2012
Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Desmoplastic Small Round Cell Tumor; Adult Epithelioid Hemangioendothelioma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Malignant Fibrous Histiocytoma; Adult Malignant Hemangiopericytoma; Adult Malignant Mesenchymoma; Adult Neurofibrosarcoma; Adult Synovial Sarcoma; Dermatofibrosarcoma Protuberans; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: pazopanib hydrochloride; Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: placebo; Procedure: therapeutic conventional surgery; Radiation: external beam radiation therapy; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Condition: Solid Tumors
Interventions: Drug: dalotuzumab; Drug: dalotuzumab; Drug: ridaforolimus
Sponsors: Merck; Merck
Recruiting - verified May 2012
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Pazopanib; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline; National Comprehensive Cancer Network
Recruiting - verified April 2012
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Lenalidomide
Sponsors: University of California, Davis; University of California, Davis; Celgene Corporation
Not yet recruiting - verified April 2012
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Condition: Myeloma
Interventions: Drug: Pomalidomide; Drug: Dexamethasone; Drug: Cyclophosphamide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified May 2012
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Drug: retaspimycin HCl (IPI-504) and everolimus
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified August 2011
Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ponatinib; Drug: G-CSF (Filgrastim); Drug: Rituximab; Drug: Methotrexate; Drug: Cytarabine; Drug: Solu-medrol ( Methyl Prednisolone); Drug: Citrovorum (Leucovorin); Drug: Prednisone; Drug: Pegfilgrastim (Neulasta)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ariad Pharmaceuticals
Recruiting - verified May 2012
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals; The Children's Tumor Foundation
Recruiting - verified January 2012
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Condition: Lymphoblastic Lymphoma
Interventions: Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine; Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine; Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine; Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide; Drug: Intrathecal chemotherapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National University, Singapore
Recruiting - verified April 2012
History of the KSHV Inflammatory Cytokine Syndrome (KICS)

Conditions: KSHV Inflammatory Cytokine Syndrome (KICS); KSHV; HHV-8
Interventions: Drug: Zidovudine/Valgancyclovir; Drug: Rituximab/Liposoma Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
Temsirolimus In Phase 0

Condition: Advanced Cancer
Intervention: Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

Conditions: Lymphoma, Diffuse Large-Cell B-cell; Diffuse, Large B-cell Lymphoma; Lymphoma, Diffuse Large-Cell; Large-Cell Lymphoma, Diffuse
Interventions: Drug: MLN4924; Drug: Etoposide; Drug: Prednisone; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Rituximab; Drug: Filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Not yet recruiting - verified April 2012
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: lenalidomide; Biological: rituximab; Other: pharmacological study; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne

Condition: Acne Vulgaris
Interventions: Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone; Drug: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Sponsors: Zeichner, Joshua, M.D.; Zeichner, Joshua, M.D.
Recruiting - verified August 2011
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

Condition: Blepharitis
Interventions: Drug: ISV-502; Drug: Azasite; Drug: Dexamethasone; Other: Vehicle
Sponsors: InSite Vision; InSite Vision
Recruiting - verified April 2012
Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Conditions: Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Radiation: yttrium Y 90 ibritumomab tiuxetan; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Biological: rituximab
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: dexamethasone; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: pegaspargase; Drug: temsirolimus; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Condition: Renal Cell Carcinoma
Intervention: Drug: everolimus and bevacizumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); Celgene Corporation; Onyx Therapeutics, Inc.
Recruiting - verified July 2011
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

Condition: Myeloma
Interventions: Drug: Hydroxychloroquine; Drug: Rapamycin
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Conditions: Leukemia; Adult Acute Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified July 2011
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Not yet recruiting - verified March 2012
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AC220; Drug: daunorubicin; Drug: cytarabine
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Ambit Biosciences Corporation
Recruiting - verified May 2012
Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

Condition: Juvenile Neuronal Ceroid Lipofuscinosis
Interventions: Drug: Mycophenolate mofetil; Drug: Liquid Placebo
Sponsors: University of Rochester; University of Rochester; Batten Disease Support and Research Association; FDA Office of Orphan Products Development
Recruiting - verified July 2011
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Conditions: Hematologic Malignancies; Acute Leukemia; Myelodysplastic Syndrome (MDS); Specific Subtypes of Refractory Anemia (RA) or Refractory Anemia With Ringed Sideroblasts(RARS) Subtypes; Myeloproliferative Disorder (MPD); Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Myeloma; Aplastic Anemia
Interventions: Drug: Fludarabine; Drug: Thiotepa; Radiation: Total Body Irradiation (TBI); Biological: Donor Lymphocyte Infusion (DLI); Drug: Cyclophosphamide (CY); Drug: Tacrolimus; Drug: Mycophenolate mofetil; Device: Hematopoietic stem cell transplantation
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Conditions: Cognitive/Functional Effects; Fatigue; Lymphoma; Neurotoxicity; Therapy-related Toxicity
Interventions: Biological: rituximab; Drug: bortezomib; Drug: dexamethasone; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Combination Trial MSC1936369B With Temsirolimus

Condition: Advanced Solid Tumor
Intervention: Drug: MEK inhibitor MSC1936369B and Temsirolimus
Sponsors: EMD Serono; EMD Serono
Recruiting - verified April 2012
Post T-plant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidate Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Conditions: Neural Tube Defects; Anemia; Leukemia, Myeloid; Bone Marrow Transplant Failure; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders
Interventions: Drug: CIK cells; Drug: Cyclosporine; Drug: Mycophenolate Mofetil; Drug: Thymoglobulin
Sponsors: Stanford University; Stanford University
Recruiting - verified July 2011
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg; Drug: Lenalidomide 25mg
Sponsors: Boston VA Research Institute, Inc.; Boston VA Research Institute, Inc.; Celgene Corporation; Kansas City Veteran Affairs Medical Center; VA Pittsburgh Healthcare System; VA Greater Los Angeles Healthcare System; Michael Debakey Veterans Affairs Medical Center; Edward Hines Jr. VA Hospital
Recruiting - verified September 2011
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: ixabepilone; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified July 2011
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Sarcoma; Gynecologic Cancer
Interventions: Drug: Doxorubicin; Drug: Sildenafil
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University
Recruiting - verified April 2012
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

Condition: Low and Intermediate 1 Risk MDS
Intervention: Drug: Lenalidomide and azacitidine combination
Sponsors: Rush University Medical Center; Rush University Medical Center; Celgene Corporation
Recruiting - verified June 2011
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib; Drug: Lenalidomide; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Incyte Corporation
Recruiting - verified March 2012
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

Condition: Kidney Transplant Rejection
Interventions: Drug: everolimus; Drug: cyclosporine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: bacilli calmette-guerin (BCG); Drug: lenalidomide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified April 2012
Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations

Conditions: Diabetes; Immunosuppression
Intervention: Procedure: Gastric emptying test
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; Novartis Pharmaceuticals
Recruiting - verified June 2011
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors: Duke University; Duke University; Celgene Corporation; Genzyme
Recruiting - verified January 2012
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

Condition: Cancer
Interventions: Procedure: Insertion of Pressure Equalization (PE) Tubes; Drug: Sodium Thiosulfate (STS); Other: Saline (Placebo); Drug: Cisplatin
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study Assessing Double-masKed Uveitis tReAtment

Condition: Uvea; Posterior, Disorder
Interventions: Drug: DE-109; Drug: DE-109; Drug: DE-109
Sponsors: Santen Inc.; Santen Inc.
Recruiting - verified June 2011
A Study Being Conducted at Multiple Locations to Compare the Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia Subjects ≥ 65 Years of Age

Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine; Drug: Lenalidomide - single agent; Drug: Lenalidomide in combination
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Amrubicin; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Aspirin
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified October 2011
A Rollover Study for Subjects Who Participated in Other Romidepsin Protocols

Conditions: Lymphoma; Cancer
Intervention: Drug: Romidepsin
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified October 2011
Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

Conditions: Esophageal Cancer; Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions: Drug: Azacitidine; Drug: Azacitidine; Drug: Azacitidine; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Epirubicin; Drug: Epirubicin; Drug: Capecitabine; Drug: Capecitabine
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University
Recruiting - verified June 2011
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Anti-CXCR4 (BMS-936564); Biological: Lenalidomide; Biological: Dexamethasone; Biological: Anti-CXCR4 (BMS-936564); Biological: Bortezomib; Biological: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified August 2011
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

Conditions: Urethral Neoplasms; Neoplasms, Urethral; Ureter Cancer; Cancer of the Urethra; Urethral Cancer
Interventions: Drug: Gemcitabine; Drug: Carboplatin; Drug: Lenalidomide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: PF-04691502; Drug: PD-0325901; Drug: PF-04691502; Drug: irinotecan; Drug: PF-05212384; Drug: irinotecan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: alvocidib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: mitoxantrone hydrochloride
Sponsors: National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Bacterial Infection; Leukemia; Lymphoma
Interventions: Biological: pneumococcal polyvalent vaccine; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified September 2011
Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) Versus "7+3" for Newly (AML)

Condition: Acute Myelogenous Leukemia
Interventions: Drug: FLAM; Drug: 7&3
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012
Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Biological: Allogeneic Myeloma Vaccine
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; Celgene Corporation
Recruiting - verified March 2012
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Interventions: Drug: Lenalidomide; Drug: Sorafenib
Sponsors: Indiana University; Indiana University School of Medicine; Celgene Corporation
Recruiting - verified December 2011
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

Condition: Hematological Malignancies
Interventions: Radiation: Total Body Irradiation; Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Fludarabine; Drug: Thiotepa; Genetic: Hematopoietic stem cell transplantation
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified January 2012
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors

Condition: Solid Tumor Malignancy
Intervention: Drug: BEZ235
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Novartis
Recruiting - verified August 2011
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Conditions: Neurofibromatosis Type 2; Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
Sponsors: House Research Institute; House Research Institute; Novartis Pharmaceuticals
Not yet recruiting - verified January 2012
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor; Breast Cancer; Non Small Cell Lung Cancer; Melanoma; Colorectal Cancer
Intervention: Drug: MSC1936369B and SAR245409
Sponsors: EMD Serono; EMD Serono; Sanofi
Recruiting - verified April 2012
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Condition: Metastatic Urothelial Carcinoma
Intervention: Drug: Lenalidomide
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Celgene Corporation
Recruiting - verified October 2011
The ABSORB BTK (Below The Knee) Clinical Investigation

Conditions: Atherosclerosis; Peripheral Artery Disease; Peripheral Vascular Disease; PAD; Claudication; Critical Limb Ischemia; Lower Limb Disease; Peripheral Arterial Occlusive Disease; PAOD; PVD
Intervention: Device: Everolimus Eluting BVS
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2012
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: everolimus; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres; Procedure: PVA, lipiodol, doxorubicin
Sponsors: Merit Medical Systems, Inc.; Merit Medical Systems, Inc.
Recruiting - verified January 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin; Drug: Seliciclib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified March 2012
Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

Conditions: Ewing's Sarcoma; Osteosarcoma; Astrocytoma; Atypical Teratoid/Rhabdoid Tumor; Ependymoma; Germ Cell Tumor; Glioma; Medulloblastoma; Rhabdoid Tumor; Retinoblastoma; Clear Cell Sarcoma; Renal Cell Carcinoma; Wilms Tumor; Hepatoblastoma; Neuroblastoma; Rhabdomyosarcoma
Intervention: Drug: sirolimus
Sponsors: Emory University; Emory University; Children's Healthcare of Atlanta
Recruiting - verified October 2011
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; B Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Bendamustine; Drug: Rituximab
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

Condition: Anal Cancer
Interventions: Drug: Tempol; Drug: 5-Fluorouracil; Drug: Mitomycin-C; Procedure: Radiation Therapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Condition: Melanoma
Intervention: Drug: Ipilimumab, Melphalan and Dactinomycin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011
Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Metformin; Drug: Vincristine; Drug: Dexamethasone; Drug: PEG-asparaginase; Drug: Doxorubicin; Drug: Intrathecal chemotherapy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Pediatric Cancer Foundation
Recruiting - verified April 2012
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Condition: Her2normal
Intervention: Drug: eribulin mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified February 2012
Stage I/II Nasal NK Cell Lymphoma

Condition: Lymphoma
Interventions: Radiation: Radiation; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: lenalidomide; Biological: rituximab
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; Celgene Corporation
Recruiting - verified November 2011
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: Rituximab; Drug: Imatinib; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Mesna; Drug: VSLI; Drug: Solu-Medrol; Drug: Methotrexate; Drug: Ara-C; Drug: G-CSF; Drug: Pegfilgrastim; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Talon Therapeutics, Inc
Not yet recruiting - verified May 2012
Research Study of ATG and Rituximab in Renal Transplantation

Condition: Acute Kidney Injury
Interventions: Drug: ATG; Drug: Rituximab; Drug: Methylprednisolone; Drug: Diphenhydramine; Drug: Acetaminophen; Drug: Tacrolimus; Drug: Sirolimus; Drug: Hydrocortisone; Drug: Prednisone
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Recruiting - verified August 2011
SOM 230 and Everolimus in Combination for the Treatment of Prostate Cancer

Conditions: Castrate Resistant Prostate Cancer; Chemotherapy Naive Prostate Cancer; Prostate Cancer
Interventions: Drug: Pasireotide; Drug: Combination treatment with SOM230 and Everolimus
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Novartis Pharmaceuticals
Recruiting - verified January 2012
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Pomalidomide
Sponsors: Yale University; Yale University; Celgene Corporation
Recruiting - verified July 2011
Immunosuppressive Medications for Participants in NIS01

Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Sirolimus; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Mycophenolic acid
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Immune Tolerance Network (ITN)
Available - verified April 2012
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus; Drug: Vinorelbine; Drug: Trastuzumab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Sirolimus; Drug: Tacrolimus; Drug: Lenalidomide
Sponsors: Indiana University; Indiana University School of Medicine; Celgene Corporation
Recruiting - verified January 2012
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Secondary Acute Myeloid Leukemia
Interventions: Radiation: Indium-111 111In anti-CD45 monoclonal antibody BC8 (dosimetric dose); yttrium Y 90 anti-CD45 monoclonal antibody BC8 (therapeutic dose); Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: flow cytometry; Genetic: cytogenetic analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)

Condition: Advanced Cancer
Interventions: Drug: ridaforolimus; Drug: MK-0752; Drug: MK-2206
Sponsors: Merck; Merck
Recruiting - verified May 2012
VTX-2337 and Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center
Recruiting - verified December 2011
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

Condition: Tuberous Sclerosis Complex
Intervention: Drug: RAD001
Sponsors: Children's Hospital Boston; Mustafa Sahin; Tuberous Sclerosis Alliance; Autism Speaks; Novartis Pharmaceuticals; Seizure Tracker LLC
Recruiting - verified February 2012
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Condition: Leukemia
Interventions: Drug: Clofarabine; Drug: Idarubicin; Drug: Cytarabine; Drug: Fludarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Condition: Non Hodgkin's Lymphoma
Intervention: Drug: REVLIMID®, Rituxan®
Sponsors: University of California, Davis; University of California, Davis; Celgene Corporation
Recruiting - verified April 2012
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Conditions: Leukemia; Lymphoma; Neuroblastoma; Sarcoma; Desmoplastic Small Round Cell Tumor
Interventions: Drug: Melphalan; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: Etoposide; Drug: Filgrastim; Biological: NK-DLI Infusions
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Conditions: Head and Neck Neoplasms; Cancer of the Head and Neck
Intervention: Drug: Carboplatin, cetuximab and RAD001
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified November 2011
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: everolimus; Drug: imatinib mesylate; Genetic: protein expression analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2011
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

Condition: Non-Hodgkins Lymphoma
Interventions: Drug: Velcade; Drug: Temsirolimus
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Millennium Pharmaceuticals, Inc.; Pfizer
Recruiting - verified December 2011
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer

Condition: Liver Neoplasms
Intervention: Drug: Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: ICM plus Olaparib; Drug: ICM without Olaparib
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas

Conditions: Low Grade Glioma; Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Oligoastrocytoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus; Drug: carboplatin; Drug: pegylated liposomal doxorubicin hydrochloride; Other: laboratory biomarker analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Lapatinib and RAD-001
Sponsors: University of Kansas; University of Kansas
Recruiting - verified October 2011
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Cancer of the Breast
Intervention: Drug: Lapatinib and Everolimus
Sponsors: Emory University; Emory University
Recruiting - verified January 2012
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: Everolimus; Drug: Pasireotide; Drug: Everolimus and Pasireotide
Sponsors: Emory University; Emory University; Novartis
Recruiting - verified April 2012
Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Condition: Adult T Cell Leukemia/Lymphoma
Intervention: Drug: Lenalidomide
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified October 2011
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Condition: Neoplasm Metastases
Interventions: Drug: Sequence 1; Drug: Sequence 2; Drug: Sequence 1; Drug: Sequence 2
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine; Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

Condition: Acute Myelogenous Leukemia (AML)
Intervention: Drug: AT-406 in combination with daunorubicin and cytarabine
Sponsors: Ascenta Therapeutics; Ascenta Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified January 2012
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Condition: Bladder Cancer
Intervention: Drug: Everolimus and Intravesical Gemcitabine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified March 2012
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified February 2011
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide phosphate; Drug: fludarabine phosphate; Drug: leucovorin calcium; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Conditions: Endometrial Cancer; Ovarian Cancer
Interventions: Drug: Ridaforolimus; Drug: Paclitaxel; Drug: carboplatin
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Recruiting - verified April 2012
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Condition: Uveal Melanoma
Intervention: Drug: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: sorafenib tosylate; Genetic: cytogenetic analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Other: laboratory biomarker analysis; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: clofarabine; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Genetic: fluorescence in situ hybridization; Procedure: peripheral blood stem cell transplantation; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

Conditions: Colorectal Cancer; Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011
Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant

Condition: Hematologic Neoplasms
Intervention: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Sponsors: Northside Hospital, Inc.; Northside Hospital, Inc.; Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)

Condition: Neoplasms Malignant
Interventions: Drug: dalotuzumab + MK-2206; Drug: dalotuzumab + MK-0752; Drug: Dalotuzumab + MK-8669 (ridaforolimus)
Sponsors: Merck; Merck
Recruiting - verified May 2012
Carfilzomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: carfilzomib and pegylated liposomal doxorubicin; Drug: carfilzomib and pegylated liposomal doxorubicin hydrochloride; Drug: carfilzomib and pegylated liposomal doxorubicin; Drug: Carfilzomib and PLD Efficacy
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

Condition: Advanced Myeloma.
Interventions: Biological: Prevnar- Pneumococcal Conjugate Vaccine (PCV); Other: Activated/costimulated autologous T-cell; Drug: Lenalidomide; Biological: MAGE-A3, Hiltonol® (Poly-ICLC)
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania; University of Pennsylvania
Recruiting - verified May 2012
Escalating Doses Thalidomide+Bortezomib+HIgh Dose Melphalan for Auto PBSC Transplant in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Thalidomide+Melphalan +Bortezomib+stem cell tranplant
Sponsors: Hackensack University Medical Center; Hackensack University Medical Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified October 2011
MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Condition: Kidney Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: everolimus
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Condition: Myelodysplastic Syndromes
Interventions: Drug: Lenalidomide 50 mg/day Days 1-28; Drug: Lenalidomide 10 mg/day
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: lenalidomide
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified January 2012
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: cytarabine; Drug: dasatinib; Drug: daunorubicin hydrochloride
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead

Condition: Hepatocellular Carcinoma
Intervention: Device: transarterial chemoembolization using a drug-eluting bead
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Acute Myeloid Leukemia/Transient Myeloproliferative Disorder; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Childhood Burkitt Lymphoma; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Anemia With Excess Blasts; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenström Macroglobulinemia
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: sirolimus; Drug: mycophenolate mofetil; Other: flow cytometry; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Conditions: Adenocarcinoma of the Esophagus; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Mixed Adenocarcinoma of the Stomach; Stage IV Esophageal Cancer; Stage IV Gastric Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: everolimus; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide and Radiation Therapy in Treating Young Patients With Pontine Glioma or High-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); NCI - Pediatric Oncology Branch; National Cancer Institute (NCI)
Recruiting - verified November 2011
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Condition: Breast Cancer
Interventions: Drug: Ridaforolimus + Dalotuzumab; Drug: Ridaforolimus; Drug: Dalotuzumab
Sponsors: Merck; Merck
Recruiting - verified May 2012
Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas

Conditions: Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; High Grade Glioma
Interventions: Drug: Lenalidomide; Radiation: Radiation Therapy
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of Everolimus (RAD001)in Combination With Lenalidomide

Condition: Solid Organ Malignancies
Intervention: Drug: Lenalidomide; Everolimus (RAD001)
Sponsors: Emory University; Emory University; Celgene Corporation; Novartis
Recruiting - verified February 2012
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Bevacizumab; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Symptom Burden in Head and Neck Cancer

Condition: Head And Neck Cancer
Interventions: Other: Placebo; Drug: Curcumin; Drug: Armodafinil; Drug: Minocycline; Drug: Bupropion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified March 2012
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Condition: Multiple Myeloma
Interventions: Drug: VELCADE; Drug: Lenalidomide; Drug: Dexamethasone; Drug: DVT prophylaxis; Drug: Bisphosphonates; Drug: Liposomal doxorubicin; Drug: Dexamethasone
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse

Conditions: Patients With Multiple Myeloma Experiencing a; First or Second Relapse
Intervention: Drug: IPH2101 combined to lenalidomide
Sponsors: Innate Pharma; Innate Pharma
Recruiting - verified October 2011
Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Ridaforolimus
Sponsors: Brown University; Debora G. Isdale; Rhode Island Hospital; The Miriam Hospital; Memorial Hospital of Rhode Island; Roger Williams Medical Center
Recruiting - verified May 2012
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: bortezomib; Drug: dexamethasone; Other: laboratory biomarker analysis; Other: gene expression analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified October 2010
Randomized, Blinded Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and TNF-α Release

Condition: Chemobrain
Intervention: Drug: Mesna
Sponsors: University of Kentucky; University of Kentucky
Recruiting - verified May 2012
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Condition: Hematologic Malignancies
Interventions: Other: Fludarabine, Cytoxan, TBI, Sirolimus; Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF; Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

Condition: Hodgkin Disease
Intervention: Drug: Lenalidomide
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Conditions: Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance; Celgene Corporation
Recruiting - verified December 2011
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Blockade in Combination With Targeted Agents

Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Condition: Breast Cancer
Interventions: Device: Focused Microwave Thermotherapy; Drug: Chemotherapy (control)
Sponsors: Medifocus, Inc.; Medifocus, Inc.
Recruiting - verified August 2011
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

Conditions: Mouth Neoplasms; Head and Neck Neoplasms; Tongue Neoplasms; Carcinoma, Squamous Cell
Interventions: Drug: Rapamycin; Procedure: Biopsy; Procedure: Dynamic CT Perfusion; Procedure: Positron Emission Tomography; Procedure: Measurement Serum Cytokines
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified February 2012
Pomalidomide for Relapse/Refractory Waldenstrom's

Conditions: Lymphoma; Myeloma
Interventions: Drug: Pomalidomide; Drug: Pomalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified February 2012
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma

Conditions: Lymphoma; Nonneoplastic Condition
Interventions: Biological: rituximab; Drug: EPOCH regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: trabectedin; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Sarcoma Alliance for Research through Collaboration
Recruiting - verified November 2011
Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Interventions: Drug: TL32711; Drug: TL32711
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Recruiting - verified November 2011
Avastin/Torisel With Carboplatin, Taxol, or Sorafenib

Condition: Advanced Cancer
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Sorafenib; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Condition: Kidney Cancer
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified April 2012
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

Condition: AML
Interventions: Drug: Sirolimus; Drug: MEC (Mitoxantrone, Etoposide, and Cytarabine)
Sponsors: Thomas Jefferson University; Thomas Jefferson University; University of Pennsylvania
Recruiting - verified January 2012
A Study of IMC-3G3 in Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Interventions: Biological: IMC-3G3; Drug: doxorubicin; Drug: dexrazoxane
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Kidney Cancer

Conditions: Solid Tumor; Kidney Cancer
Interventions: Drug: pazopanib; Drug: everolimus
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; GlaxoSmithKline; Novartis
Recruiting - verified February 2012
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Condition: Advanced Cancers
Interventions: Drug: Lenalidomide; Drug: Bevacizumab; Drug: Sorafenib; Drug: Temsirolimus; Drug: Lenalidomide; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012
Tandem Auto-Allo Transplant for Lymphoma

Conditions: Diffuse, Large B-Cell, Lymphoma; Lymphoma, Low-Grade; T-Cell Lymphoma; Mantle-Cell Lymphoma; Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Lymphoma, Small Lymphocytic
Interventions: Drug: Busulfan; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Mesna; Drug: Phenytoin; Drug: Ursodiol; Other: Infusion of autologous peripheral blood stem cells; Drug: Neupogen; Drug: Fludarabine; Drug: Busulfan; Other: Peripheral blood stem cell transplant; Drug: Tacrolimus; Drug: Sirolimus; Drug: Methotrexate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute
Recruiting - verified April 2012
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Conditions: Bladder Cancer; Renal Pelvis Cancer; Ureter Cancer
Intervention: Drug: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Novartis Pharmaceuticals
Recruiting - verified April 2012
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: temsirolimus; Drug: temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Kidney Allograft Dysfunction Without Reversible Causes

Condition: Kidney Graft Dysfunction
Interventions: Drug: Cyclosporins/Tacrolimus; Drug: Sirolimus
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified December 2011
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Doxorubicin; Drug: Bortezomib; Drug: Bendamustine; Drug: Filgrastim
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Cephalon
Recruiting - verified March 2012
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Condition: Neuroblastoma
Interventions: Drug: busulfan; Drug: cisplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: irinotecan hydrochloride; Drug: isotretinoin; Drug: melphalan; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Other: pharmacological study; Other: questionnaire administration; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: iobenguane I 131
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Procedure: umbilical cord blood transplantation; Drug: fludarabine phosphate; Drug: cyclophosphamide; Procedure: ex vivo-expanded cord blood progenitor cell infusion; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Conditions: Prostate Cancer; Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: vorinostat; Drug: temsirolimus; Other: laboratory biomarker analysis; Procedure: positron emission tomography/computed tomography
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute
Recruiting - verified March 2012
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Rituximab; Drug: Etoposide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2010
Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-

Condition: Kidney Transplant
Interventions: Drug: Sirolumus; Drug: Tacrolimus
Sponsors: The Cleveland Clinic; The Cleveland Clinic
Recruiting - verified January 2012
Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

Condition: Soft Tissue Sarcoma
Interventions: Drug: doxorubicin in combination with palifosfamide-tris; Drug: doxorubicin in combination with placebo
Sponsors: ZIOPHARM; ZIOPHARM
Recruiting - verified April 2012
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Drug: panobinostat; Drug: everolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Other: liquid chromatography; Other: mass spectrometry; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Cancer Institute (NCI); Novartis
Recruiting - verified April 2012
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma
Interventions: Drug: bortezomib; Drug: fludarabine phosphate; Other: melphalan; Radiation: intensity-modulated radiation therapy; Radiation: total marrow irradiation; Radiation: tomotherapy; Drug: tacrolimus; Drug: sirolimus
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: paclitaxel
Sponsors: University of Kansas; University of Kansas; Novartis
Recruiting - verified October 2011
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

Condition: Glioma
Intervention: Drug: RAD001 (Everolimus)
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Children's Hospital Boston; Children's Hospital of Philadelphia; Children's Research Institute; Children's Hospital Medical Center, Cincinnati; National Cancer Institute (NCI); University of Chicago; University of Utah; Washington University School of Medicine
Recruiting - verified May 2012
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Prostate Cancer; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Drug: doxorubicin-GnRH agonist conjugate AEZS-108
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; AEterna Zentaris
Recruiting - verified May 2012
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: azacitidine; Drug: lenalidomide; Drug: dexamethasone; Other: DNA methylation analysis; Other: gene expression analysis; Other: bone marrow aspiration; Other: immunohistochemistry staining method; Other: reverse transcriptase-polymerase chain reaction; Other: flow cytometry
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma

Conditions: Cancer; Leukemia; Lymphoma
Intervention: Drug: Sirolimus and Methotrexate
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; The Leukemia and Lymphoma Society
Recruiting - verified November 2011
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Conditions: End Stage Renal Disease; Renal Transplant
Interventions: Drug: Anti-Thymocyte Globulin; Drug: TOL101; Drug: TOL101; Drug: Steroids; Drug: Tacrolimus; Drug: Mycophenolate mofetil (MMF)
Sponsors: Tolera Therapeutics, Inc; Tolera Therapeutics, Inc
Recruiting - verified September 2011
Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Conditions: Kidney Transplantation; Renal Transplantation; Reperfusion Injury
Interventions: Drug: Myfortic (mycophenolic acid); Drug: Myfortic (mycophenolic acid); Drug: Thymoglobulin (anti-thymocyte globulin); Drug: Thymoglobulin (anti-thymocyte globulin)
Sponsors: Georgetown University; Georgetown University; Novartis
Recruiting - verified October 2011
Laboratory-Treated T Cells After Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

Condition: Advanced Cancer
Intervention: Drug: FLT-PET
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: sorafenib with everolimus
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: bendamustine hydrochloride; Drug: idarubicin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation; Drug: Lenalidomide maintenance
Sponsors: Indiana University; Indiana University School of Medicine; Celgene Corporation
Recruiting - verified March 2012
Randomized Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Condition: Head and Neck Cancer
Interventions: Drug: Everolimus escalating dose; Drug: Everolimus or Placebo
Sponsors: University of Chicago; University of Chicago; Novartis Pharmaceuticals
Recruiting - verified June 2011
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: E7080; Drug: Everolimus; Drug: E7080 plus Everolimus
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

Conditions: Myelodysplastic Syndrome; MDS
Interventions: Drug: Prednisone; Drug: Lenalidomide
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012
Cetuximab and Lenalidomide in Head and Neck

Condition: Squamous Cell Carcinoma
Intervention: Drug: Cetuximab and Lenalidomide
Sponsors: University of Chicago; University of Chicago; Celgene Corporation
Recruiting - verified June 2011
RAD001 Plus Carboplatin in Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: RAD001
Sponsors: New York University School of Medicine; New York University School of Medicine; Novartis Pharmaceuticals
Recruiting - verified December 2011
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

Conditions: Renal Cell Cancer; Kidney Cancer
Interventions: Drug: Sunitinib; Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2012
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Pomalidomide
Sponsors: University of Arkansas; University of Arkansas; Celgene Corporation
Recruiting - verified February 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

Condition: Neoplasm Metastases
Intervention: Drug: RAD001 + AMG479
Sponsors: Indiana University; Indiana University; Amgen; Novartis
Recruiting - verified December 2011
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2012
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: management of therapy complications; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ofatumumab, Lenalidomide
Sponsors: Medical University of South Carolina; Medical University of South Carolina; GlaxoSmithKline; Celgene Corporation
Recruiting - verified November 2011
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Condition: Liver Transplant Recipient
Interventions: Drug: Tacrolimus; Drug: Tacrolimus + everolimus; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Comprehensive Cancer Network; Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified May 2012
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Condition: Advanced Non-clear Cell Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: Duke University; Duke University; Novartis; Pfizer
Recruiting - verified February 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone; Drug: Sirolimus + prednisone
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified April 2012
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

Conditions: Burkitt Lymphoma; Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions: Drug: rituximab; Drug: etoposide; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone; Drug: filgrastim
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Conditions: Indolent Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma
Interventions: Drug: CAL-101; Drug: Rituximab; Drug: Bendamustine; Drug: Ofatumumab; Drug: Fludarabine; Drug: Everolimus; Drug: Bortezomib; Drug: Chlorambucil
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer
Interventions: Drug: lenalidomide; Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Other: questionnaire administration
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified August 2011
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

Conditions: Thymoma; Thymic Carcinoma
Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Everolimus; Drug: Rituximab; Drug: Bortezomib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Novartis; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

Condition: Stages II-III Breast Cancer
Interventions: Drug: Nanoparticle Albumin Bound Paclitaxel; Drug: doxorubicin; Drug: cyclophosphamide
Sponsors: University of South Alabama; University of South Alabama; Celgene Corporation
Recruiting - verified August 2011
Lapatinib With Sirolimus or Metformin

Condition: Advanced Cancers
Interventions: Drug: Lapatinib; Drug: Sirolimus; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Sirolimus and Vorinostat in Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified February 2012
Lenalidomide and High-Dose Melphalan

Conditions: Myeloma; Stem Cell Transplantation
Interventions: Drug: Lenalidomide; Drug: Melphalan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Drug: lenalidomide; Drug: temsirolimus; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified November 2010
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: pomalidomide; Drug: dexamethasone; Drug: rituximab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation
Recruiting - verified June 2011
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: everolimus; Drug: lenalidomide; Other: laboratory biomarker analysis; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: fluorescence in situ hybridization
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified March 2012
Calcineurin Inhibitor Sparing After Kidney Transplantation

Condition: CNI Side Effects
Interventions: Drug: Cyclosporine & Cellcept; Drug: Prograf & Cellcept; Drug: Cyclosporine, Cellcept, & Prednisone; Drug: Prograf, Cellcept, & Prednisone; Drug: Low Dose CNI (Cyclosporine or FK) and Cellcept; Drug: Rapamune and Cellcept; Drug: Low dose CNI (CSA or FK), Rapamune, & Prednisone; Drug: Rapamune, Cellcept, & Prednisone
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Roche Pharma AG; Wyeth is now a wholly owned subsidiary of Pfizer; Genzyme
Recruiting - verified April 2012
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: RAD001 (in addition to standard radiation and chemotherapy)
Sponsors: University of Chicago; University of Chicago; Novartis Pharmaceuticals
Recruiting - verified June 2011
A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer

Condition: Advanced Solid Tumors
Intervention: Drug: AMG 479, Everolimus, Panitumumab
Sponsors: Duke University; Duke University; Amgen; Novartis Pharmaceuticals
Recruiting - verified December 2011
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Conditions: Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: carfilzomib; Drug: cyclophosphamide; Drug: thalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Docetaxel and Sirolimus in Patients With Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Docetaxel (Taxotere); Drug: Sirolimus (Rapamycin); Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Lenalidomide in Treating Patients With AIDS-Related Kaposi Sarcoma

Conditions: Nonneoplastic Condition; Sarcoma
Interventions: Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Lenalidomide; Drug: ofatumumab
Sponsors: University of Nebraska; University of Nebraska; Celgene Corporation; GlaxoSmithKline
Recruiting - verified February 2012
Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation

Condition: Kidney Transplantation
Interventions: Drug: Mycophenolic Acid; Drug: Standard of Care: CNI and MPA
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Recruiting - verified November 2011
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Prednisone; Drug: Dexamethasone
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Condition: Prostate Cancer
Interventions: Drug: carboplatin; Drug: everolimus; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer

Condition: Advanced Solid Tumors
Intervention: Drug: Temsirolimus and capecitabine
Sponsors: Georgetown University; Georgetown University; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified April 2012
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: perifosine; Drug: temsirolimus; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2011
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors

Condition: Pediatric Solid Tumors
Intervention: Drug: perifosine + temsirolimus
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; Duke University; NATL COMP CA NETWORK; Pfizer; Keryx / AOI Pharmaceuticals, Inc.
Recruiting - verified November 2011
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Condition: Refractory Multiple Myeloma
Interventions: Drug: bendamustine hydrochloride; Drug: lenalidomide; Drug: dexamethasone
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: therapeutic autologous lymphocytes; Drug: azacitidine; Drug: lenalidomide
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified April 2012
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Biological: rituximab; Drug: cyclophosphamide; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Open Label Pilot Study of Apremilast in Treatment of Rosacea

Conditions: Erythematotelangiectatic Rosacea; Papulopustular Rosacea
Intervention: Drug: Apremilast
Sponsors: Columbia University; Columbia University; Celgene Corporation
Recruiting - verified February 2012
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Condition: Leukemia
Interventions: Drug: 5-Azacytidine; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified April 2012
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified April 2012
Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Carcinoma
Interventions: Drug: Pazopanib; Drug: Doxil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; GlaxoSmithKline
Recruiting - verified November 2011
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified March 2012
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Condition: Acute Myeloid Leukemia
Intervention: Drug: Elacytarabine plus idarubicin
Sponsors: Clavis Pharma; Clavis Pharma; Theradex; INC Research Limited
Recruiting - verified February 2012
Stem Cell Transplant for Epidermolysis Bullosa

Condition: Epidermolysis Bullosa
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Anti-thymocyte globulin; Drug: Cyclosporine A; Drug: Mycophenolate mofetil; Procedure: Hematopoietic stem cell transplant; Procedure: Mesenchymal stem cell transplant; Radiation: Total body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Conditions: Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma
Interventions: Drug: Cylcophosphamide; Drug: Etoposide; Drug: Alemtuzumab; Drug: Doxorubicin; Drug: Prednisone; Drug: Filgrastim; Drug: Rituximab; Drug: Vincristine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified May 2012
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: tacrolimus; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: laboratory biomarker analysis; Procedure: flow cytometry; Radiation: total-body irradiation; Genetic: fluorescence in situ hybridization; Genetic: western blotting; Procedure: polymerase chain reaction; Biological: filgrastim
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Condition: Sarcoma
Interventions: Drug: PCI-24781; Drug: Doxorubicin
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Pharmacyclics
Recruiting - verified April 2012
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Biological: anti-thymocyte globulin; Biological: rituximab; Drug: busulfan; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: methotrexate; Drug: sirolimus; Drug: tacrolimus; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q

Condition: Anemia
Interventions: Drug: Lenalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Dose Dense MVAC for Muscle Invasive Bladder Cancer

Conditions: Muscle Invasive Bladder Cancer; High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Intervention: Drug: single arm dose dense MVAC
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center
Recruiting - verified March 2012
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma

Conditions: Thymoma; Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb
Recruiting - verified January 2012
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Conditions: Squamous Cell Cancer; Head and Neck Cancer
Intervention: Drug: Temsirolimus + Weekly Paclitaxel + Carboplatin
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; NATL COMP CA NETWORK; Pfizer
Recruiting - verified January 2012
ABT-888 With or Without Mitomycin in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: mitomycin C; Drug: veliparib
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified January 2010
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus; Drug: cisplatin; Drug: cetuximab
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified March 2012
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified April 2012
Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Azacitidine and Lenalidomide; Drug: Azacitidine and Lenalidomide; Drug: Azacitidine and Lenalidomide; Drug: Azacitidine and Lenalidomide
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study

Condition: Coronary Occlusions
Intervention: Device: everolimus-eluting stent
Sponsors: North Texas Veterans Healthcare System; North Texas Veterans Healthcare System
Recruiting - verified April 2012
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Conditions: Blood Stem Cell Transplant Failure; Leukemia; Hematologic Malignancies
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Melphalan; Drug: Mesna; Drug: Rituximab; Procedure: Stem Cell Transplantation; Drug: Thiotepa; Drug: Tacrolimus; Drug: Mycofenolate mofetil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Chronic Lymphocytic Leukemia; Burkitt Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: carmustine; Drug: etoposide; Drug: cytarabine; Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: tacrolimus; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Drug: melphalan; Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Genetic: fluorescence in situ hybridization; Other: flow cytometry; Genetic: RNA analysis; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Procedure: allogeneic peripheral blood mononuclear stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

Conditions: Chronic Lymphocytic Leukemia; Leukemia
Intervention: Drug: lenalidomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Celgene Corporation
Recruiting - verified April 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma

Condition: Hepatocellular Carcinoma
Intervention: Drug: sorafenib with temsirolimus
Sponsors: University of California, San Francisco; University of California, San Francisco; Northwestern University
Recruiting - verified March 2012
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: vincristine sulfate; Other: pharmacological study
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2011
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors

Condition: Triple Negative Breast Cancer
Intervention: Drug: Temsirolimus, cisplatin, erlotinib
Sponsors: Columbia University; Columbia University; Wyeth is now a wholly owned subsidiary of Pfizer; Genentech
Recruiting - verified October 2011
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

Condition: Leukemia-Lymphoma, Adult T-Cell
Intervention: Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified May 2012
Sirolimus Conversions in African-American Renal Transplant Recipients

Condition: Kidney Transplantation
Interventions: Drug: rapamune, mycophenolate mofetil and steroid; Drug: tacrolimus, sirolimus and steroid
Sponsors: Medical University of South Carolina; Medical University of South Carolina; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified April 2012
R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Radiation: Involved field irradiation
Sponsors: Fondazione Michelangelo; Fondazione Michelangelo
Recruiting - verified February 2011
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia
Interventions: Biological: pretargeted radioimmunotherapy; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Other: pharmacological study; Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors

Conditions: Central Nervous System Embryonal Tumor; Germ Cell Tumors
Interventions: Drug: Melphalan; Drug: Carboplatin; Drug: Sodium thiosulfate; Drug: Filgrastim; Drug: Pegfilgrastim
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute
Recruiting - verified January 2012
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia

Conditions: Peripheral Blood Stem Cell Transplantation; Anemia, Sickle Cell; Graft-Versus-Host Disease; Sirolimus (Rapamune(Registered Trademark)); Alemtuzumab (Campath(Registered Trademark))
Interventions: Procedure: PBMC Transplant; Drug: Alemtuzumab (Campath(Registered Trademark)); Drug: Sirolimus (Rapamune(Registered Trademark)); Drug: Cyclophosphamide (Cytoxan(Registered Trademark)); Procedure: Low Dose Irradiation
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: LBH589; Drug: RAD001 and LBH589 as a doublet
Sponsors: Duke University; Duke University; Novartis
Recruiting - verified February 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Conditions: Kaposiform Hemangioendotheliomas; Tufted Angioma; Capillary Venous Lymphatic Malformation; Venous Lymphatic Malformation; Microcystic Lymphatic Malformation; Mucocutaneous Lymphangiomatosis and Thrombocytopenia; Capillary Lymphatic Arterial Venous Malformations; PTEN Overgrowth Syndrome With Vascular Anomaly; Lymphangiectasia Syndromes
Intervention: Drug: sirolimus
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer

Condition: Breast Cancer
Interventions: Dietary Supplement: Coenzyme Q10; Dietary Supplement: Coenzyme Q10 Placebo
Sponsors: Columbia University; Columbia University; National Institutes of Health (NIH)
Recruiting - verified October 2011
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Condition: Bladder Cancer
Interventions: Drug: Mitomycin C (MMC); Biological: Bacillus Calmette-Guerin (BCG)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; New York Presbyterian Hospital; Weill Medical College of Cornell University
Recruiting - verified January 2012
Treatment of Older Adults With Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone; Drug: Vincristine; Drug: Doxorubicin; Drug: PEG-asparaginase; Drug: Cytarabine; Drug: Methotrexate; Drug: Imatinib; Drug: Clofarabine; Drug: 6 Mercaptopurine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Enzon Pharmaceuticals, Inc.; Genzyme
Recruiting - verified April 2012
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders

Conditions: Leukemia; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; MDS; Multiple Myeloma
Interventions: Drug: EPOCH-F/R; Drug: FLAG; Drug: Transplant Preparative Regimen (Flu/Cy/Mes); Drug: GVHD Prophylaxis (tacrolimus and sirolimus); Procedure: Double Cord Blood Transplantation
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Vorinostat, Rituximab, and Combination Chemotherapy In Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat; Other: R-CHOP regimen; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes

Conditions: Cowden's Disease; Hamartoma Syndrome, Multiple
Interventions: Radiation: fludeoxyglucose F 18; Drug: sirolimus
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

Conditions: Leukemia; Acute Lymphocytic Leukemia
Interventions: Drug: Everolimus (RAD001); Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Mesna; Drug: Methotrexate; Drug: Ara-C (Cytarabine); Drug: Solu-Medrol; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified November 2011
Bortezomib and Romidepsin in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: Bortezomib; Drug: Romidepsin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

Condition: Liver Cancer
Interventions: Radiation: yttrium Y 90 glass microspheres; Drug: Cisplatin; Drug: Mitomycin; Drug: Doxorubicin
Sponsors: Northwestern University; Northwestern University; National Cancer Institute (NCI)
Recruiting - verified March 2012
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Condition: Head And Neck Cancer
Interventions: Drug: Erlotinib; Drug: RAD001
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis; OSI Pharmaceuticals
Recruiting - verified April 2012
Pomalidomide for Myelofibrosis Patients

Conditions: Polycythemia Vera; Thrombocythemia
Intervention: Drug: CC-4047
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified April 2012
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Condition: Breast Cancer
Interventions: Drug: nab-paclitaxel; Drug: trastuzumab; Drug: Doxorubicin; Drug: cyclophosphamide
Sponsors: University of Kansas; University of Kansas; Celgene Corporation
Recruiting - verified October 2011
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

Condition: Metastatic Prostate Cancer
Interventions: Drug: Bevacizumab; Drug: Lenalidomide; Drug: Docetaxel; Drug: Prednisone
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Sirolimus and Cetuximab in Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; M.D. Anderson Cancer Center; Novartis
Recruiting - verified June 2011
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Condition: Breast Cancer
Interventions: Drug: everolimus; Drug: abraxane
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Recruiting - verified October 2011
Polycystic Liver Disease in Kidney Transplant

Condition: Kidney Transplant
Interventions: Drug: Tacrolimus; Drug: Sirolimus (Rapamune, Rapamycin); Drug: Mycophenolate Mofetil + Prednisone
Sponsors: Mayo Clinic; Mayo Clinic; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified December 2011
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Condition: Lymphocytic Leukemia
Interventions: Drug: alemtuzumab; Drug: everolimus
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors: Emory University; Emory University; Merck; Celgene Corporation
Recruiting - verified April 2012
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Conditions: Advanced Non-small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012
Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

Conditions: Non-hodgkin Lymphoma; Hodgkin Lymphoma
Interventions: Drug: Sirolimus; Drug: Methotrexate; Drug: Tacrolimus; Drug: Cyclosporine; Drug: Mycophenolate mofetil
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Conditions: Renal Cell Carcinoma; Graft-Versus-Host Disease; Engraftment Syndrome
Interventions: Drug: Pentostatin; Drug: Sirolimus; Drug: Cyclophosphamide; Procedure: Allogeneic Hematopoietic Stem Cell Transplant; Procedure: Th2 Cell Transplantation; Drug: Th2 Cells in Allogeneic HSCT
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: FDG-PET; Drug: Pemetrexed; Drug: Sirolimus
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

Conditions: MonoMAC; Myelodysplastic Syndrome; Immunodeficiency
Interventions: Procedure: Reduced-Intensity Hematopoietic Stem Cell; Drug: Fludarabine; Procedure: Total Body Irradiation (TBI); Drug: Filgrastim; Drug: Sirolimus; Drug: Tacrolimus; Drug: Ursodiol
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Pemetrexed and temsirolimus
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi's Sarcoma

Condition: Sarcoma, Kaposi
Interventions: Drug: Liposomal Doxorubicin; Drug: Bevacizumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Drug: torisel
Sponsors: Oncology Specialists, S.C.; Oncology Specialists, S.C.; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified August 2010
Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Condition: Nonmalignant Neoplasm
Interventions: Procedure: umbilical cord blood transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Drug: fludarabine phosphate; Drug: treosulfan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: methotrexate; Drug: cyclosporine; Drug: mycophenolate mofetil; Genetic: DNA analysis; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis; Biological: anti-thymocyte globulin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); medac GmbH
Recruiting - verified April 2012
Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Trastuzumab (Herceptin); Drug: Trastuzumab (Herceptin) plus Everolimus
Sponsors: Emory University; Emory University; Genentech; Novartis Pharmaceuticals
Recruiting - verified November 2011
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

Conditions: Hematopoietic/Lymphoid Cancer; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; T-cell Adult Acute Lymphoblastic Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: panobinostat; Drug: everolimus; Other: laboratory biomarker analysis; Other: pharmacological study; Other: flow cytometry; Other: immunohistochemistry staining method; Other: western blotting
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified May 2012
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2011
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: enalapril maleate
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Fludarabine; Drug: Rituximab; Drug: Thymoglobulin; Procedure: Stem Cell Transplantation; Drug: Bendamustine; Drug: Allopurinol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012
Nutritional and Contractile Regulation of Muscle Growth

Condition: Sarcopenia
Interventions: Drug: Rapamycin; Other: Amino acid supplementation; Other: Low-intensity resistance exercise; Drug: Sodium nitroprusside; Device: Blood flow restriction cuff; Other: Low-intensity resistance exercise
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2012
A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Conditions: Leukemia; Amyloidosis
Interventions: Drug: Lenalidomide; Drug: Melphalan; Drug: Dexamethasone
Sponsors: Stanford University; Stanford University; Celgene Corporation
Recruiting - verified May 2012
Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

Condition: Pulmonary Veno Occlusive Disease
Intervention: Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
Sponsors: Children's Hospital Boston; Children's Hospital Boston
Recruiting - verified June 2011
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not Responded to Treatment

Conditions: Leukemia; Lymphoma
Interventions: Drug: cytarabine; Drug: decitabine; Drug: doxorubicin hydrochloride; Drug: imatinib mesylate; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: vincristine sulfate; Drug: vorinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Condition: Advanced Cancers
Intervention: Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

Conditions: Lymphoblastic Leukemia; Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin; Drug: Vincristine; Drug: PEG-asparaginase; Drug: Intrathecal Methotrexate; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Doxorubicin; Drug: Thioguanine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine and lenalidomide; Drug: BL-NHL; Drug: BLR-CLL; Drug: BLR-NHL
Sponsors: Georgetown University; Georgetown University; Celgene Corporation; Cephalon
Recruiting - verified April 2012
Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Trilineage Dysplasia (AML-TLD)

Condition: Myelodysplastic Syndrome
Intervention: Drug: Lenalidomide
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Decitabine; Drug: Rapamycin
Sponsors: University of Rochester; University of Rochester
Recruiting - verified September 2011
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma

Condition: Pleural Mesothelioma
Intervention: Drug: Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
Sponsors: Columbia University; Columbia University
Recruiting - verified October 2011
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Interventions: Drug: RAD001; Drug: erlotinib
Sponsors: University of California, San Francisco; University of California, San Francisco; Genentech; Novartis Pharmaceuticals; The V Foundation for Cancer Research
Recruiting - verified March 2012
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma

Condition: Hodgkin's Lymphoma
Intervention: Drug: Temsirolimus
Sponsors: Loyola University; Loyola University; Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting - verified September 2011
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Conditions: Non-hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma
Intervention: Drug: Oncaspar, Doxil, Decadron
Sponsors: Penn State University; Penn State University
Recruiting - verified May 2012
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Condition: Leukemia
Interventions: Drug: lenalidomide; Biological: bystander vaccine
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Celgene Corporation
Recruiting - verified February 2012
Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal

Condition: Kidney Cancer
Intervention: Drug: everolimus
Sponsors: Baylor College of Medicine; Gilad Amiel; University of Texas Southwestern Medical Center
Recruiting - verified February 2012
Lenalidomide and Decitabine in High Grade Myelodysplastic Syndromes

Condition: Myelodysplastic Syndromes
Intervention: Drug: Lenalidomide, Decitabine
Sponsors: Duke University; Duke University; Celgene Corporation
Recruiting - verified February 2012
Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma

Conditions: Low-grade Glioma; Astrocytoma; Oligodendroglioma; Mixed Oligoastrocytoma
Intervention: Drug: RAD001
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified April 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

Condition: Glioblastoma
Interventions: Drug: Sirolimus; Drug: Vandetanib
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Brigham and Women's Hospital; Dana-Farber Cancer Institute; AstraZeneca
Recruiting - verified April 2012
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant

Conditions: Hematologic Malignancies; Graft vs Host Disease
Interventions: Procedure: reduced intensity, matched related donor stem cell transplant; Drug: tacrolimus (standard GVHD prophylaxis); Drug: mycophenolate (standard GVHD prophylaxis); Drug: vorinostat
Sponsors: University of Michigan Cancer Center; Pavan Reddy, MD
Recruiting - verified February 2012
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Conditions: Urothelial Cancer; Muscle-invasive Urothelial Carcinoma
Interventions: Drug: Methotrexate; Drug: Doxorubicin; Drug: vinblastine; Drug: cisplatin; Drug: Pegfilgrastim
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Amgen
Recruiting - verified February 2012
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Condition: Multiple Myeloma
Interventions: Procedure: Stem cell transplant x 1 or x 2; Drug: lenalidomide and dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Tufts Medical Center; Lahey Clinic
Recruiting - verified January 2012
Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias

Condition: Acute Myelogenous Leukemia
Interventions: Drug: Fludarabine; Drug: Cytarabine; Drug: G-CSF (Filgrastim, Neupogen); Drug: Idarubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Chemotherapeutic Agents in Brain/Breast

Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

Condition: Hodgkin's Disease
Interventions: Drug: R-mabHD; Drug: ABVD
Sponsors: American Scitech International; American Scitech International; ImClone LLC; Bristol-Myers Squibb
Not yet recruiting - verified July 2011
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: fludarabine phosphate; Drug: treosulfan; Radiation: total-body irradiation; Procedure: umbilical cord blood transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)

Conditions: Translocation, Genetic; Sarcoma, Soft Tissue
Interventions: Drug: Trabectedin; Drug: Doxorubicin
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified May 2012
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: total-body irradiation; Drug: bortezomib; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Other: flow cytometry; Other: laboratory biomarker analysis; Drug: melphalan; Procedure: peripheral blood stem cell transplantation; Genetic: fluorescence in situ hybridization; Drug: cyclosporine; Procedure: autologous hematopoietic stem cell transplantation; Procedure: syngeneic bone marrow transplantation; Genetic: polymerase chain reaction
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Biological: graft versus host disease prophylaxis/therapy; Drug: cyclophosphamide; Drug: cytarabine; Drug: dasatinib; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: vincristine sulfate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Conditions: Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Peripheral T-cell Lymphoma; Plasma Cell Neoplasm; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Drug: tacrolimus; Radiation: total-body irradiation; Procedure: allogeneic bone marrow transplantation; Biological: natural killer cell therapy; Genetic: fluorescence in situ hybridization; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Conditions: Multiple Myeloma; Plasma Cell Neoplasm
Interventions: Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone; Drug: Lenalidomide & Dexamethasone
Sponsors: PrECOG, LLC.; PrECOG, LLC.; Celgene Corporation
Recruiting - verified April 2012
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat); Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified April 2012
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

Condition: Solid Tumor
Interventions: Drug: Bevacizumab; Drug: Temozolomide; Drug: Vincristine sulfate; Drug: Irinotecan; Drug: Cefixime or Cefpodoxime
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012
Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: lenalidomide
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Prospective Study of Rapamycin for the Treatment of SLE

Condition: Systemic Lupus Erythematosus (SLE)
Intervention: Drug: Rapamycin
Sponsors: State University of New York - Upstate Medical University; State University of New York - Upstate Medical University; Pfizer
Recruiting - verified July 2011
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Celgene Corporation; Genentech
Recruiting - verified February 2012
Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified May 2012
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Study of Temsirolimus, Topotecan, and Bortezomib

Condition: Advanced Cancer
Interventions: Drug: Torisel (Temsirolimus); Drug: Hycamtin (Topotecan); Drug: Velcade (Bortezomib)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Erlotinib and Temsirolimus for Solid Tumors

Condition: Solid Tumors
Interventions: Drug: erlotinib and temsirolimus; Drug: erlotinib and temsirolimus; Drug: erlotinib and temsirolimus; Drug: erlotinib and temsirolimus; Drug: erlotinib and temsirolimus; Drug: erlotinib and temsirolimus
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011
A Phase 1b Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer

Conditions: Cancer; Carcinoma; Fallopian Tube Cancer; Gynecological Malignancies; Metastases; Oncology; Ovarian Cancer; Solid Tumors; Tumors
Interventions: Drug: A1: AMG 386 10 mg/kg + Liposomal doxorubicin; Drug: A3: AMG 386 15mg/kg + Liposomal doxorubicin; Drug: B1: AMG 386 10 mg/kg + Topotecan; Drug: B3: AMG 386 15mg/kg + Topotecan
Sponsors: Amgen; Amgen
Recruiting - verified September 2011
A Trial of RAD001 and Avastin in Children With Recurrent Solid Tumors

Conditions: Recurrent or Refractory Solid Tumors; CNS Malignancies
Interventions: Drug: Bevacizumab; Drug: Everolimus
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Novartis Pharmaceuticals
Recruiting - verified December 2011
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

Conditions: Leukemia; Myelodysplastic Syndrome; Non-Hodgkins Lymphoma; Chronic Myelogenous Leukemia
Intervention: Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified January 2012
UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma

Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE; Drug: TT3-LITE Regimen (L-TT3)
Sponsors: University of Arkansas; University of Arkansas; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: lenalidomide; Drug: vorinostat; Procedure: quality-of-life assessment; Procedure: Correlative studies
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Merck
Recruiting - verified November 2011
Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Acute Myelomonocytic Leukemia (M4); Childhood Anaplastic Large Cell Lymphoma; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Chronic Lymphocytic Leukemia; Refractory Cytopenia With Multilineage Dysplasia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Procedure: umbilical cord blood transplantation; Drug: cyclosporine; Procedure: double-unit umbilical cord blood transplantation; Other: laboratory biomarker analysis; Procedure: biopsy; Other: immunologic technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Etoposide; Drug: Clofarabine
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genzyme; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide Plus Rituximab for Indolent Non-Hodgkin's Lymphoma

Condition: Lymphoma
Interventions: Drug: Lenalidomide; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified December 2011
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Islets of Langerhans transplantation
Sponsors: University of Illinois; University of Illinois
Recruiting - verified August 2011
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: lenalidomide; Drug: melphalan
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified February 2012
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Conditions: 714leukemia; Lymphoma
Intervention: Drug: Bortezomib (IV) and Everolimus (PO)
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI); The Leukemia and Lymphoma Society
Recruiting - verified December 2011
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: lenalidomide; Drug: prednisone; Drug: vincristine sulfate; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

Conditions: Graft vs Host Disease; Peripheral Blood Stem Cell Transplantation; Transplantation, Homologous
Interventions: Drug: Tacrolimus; Drug: Sirolimus; Drug: Bortezomib
Sponsors: Indiana University; Indiana University School of Medicine; Millennium Pharmaceuticals, Inc.
Recruiting - verified January 2012
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Conditions: Leukemia; Acute Lymphoblastic Leukemia
Interventions: Drug: Rituximab; Drug: Cyclophosphamide (CTX); Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Methotrexate (MTX); Drug: Cytarabine; Drug: G-CSF; Drug: Mesna; Drug: Pegylated asparaginase; Drug: Pegfilgrastim; Drug: Solumedrol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

Conditions: Burkitt's Lymphoma; Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: G-CSF; Drug: Cytarabine; Drug: Methotrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme

Condition: Malignant Gliomas
Interventions: Drug: Irinotecan; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified January 2012
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Conditions: Osteosarcoma; Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Biological: Bevacizumab; Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genentech; National Institutes of Health (NIH)
Recruiting - verified June 2011
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Interventions: Drug: Idarubicin; Drug: Cytarabine; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified April 2012
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Rituximab; Drug: Adriamycin; Drug: Bleomycin; Drug: Vinblastine; Drug: Dacarbazine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Condition: Neuroblastoma
Intervention: Drug: Irinotecan and Bortezomib
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified July 2011
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Procedure: hematopoietic stem cell transplantation; Drug: methylprednisolone; Drug: filgrastim; Drug: cyclosporine; Drug: Mycophenolate Mofetil
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Rituximab; Drug: Bortezomib; Drug: Lenalidomide
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Millennium Pharmaceuticals, Inc.; Celgene Corporation
Recruiting - verified November 2011
Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

Conditions: Systemic Scleroderma; Severe Systemic Sclerosis
Interventions: Drug: fludarabine phosphate; Drug: Mycophenolic Acid; Drug: tacrolimus; Radiation: total-body irradiation; Procedure: bone marrow transplantation; Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: biopsy; Drug: cyclophosphamide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Conditions: Lymphoma, B-Cell; Follicular Lymphoma
Intervention: Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
Sponsors: Emory University; Emory University; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: panitumumab; Drug: everolimus; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: ThermoDox; Drug: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified June 2011
PET Imaging of P-glycoprotein Function Using [11C]dLop

Condition: Healthy
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified April 2012
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Doxil; Drug: Carboplatin; Drug: Bevacizumab
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified October 2011
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Radiation: iodine I 131 monoclonal antibody BC8; Procedure: allogeneic bone marrow transplantation; Drug: tacrolimus; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Conditions: Graft Versus Host Disease; Leukemia; Lymphoma
Interventions: Biological: rituximab; Drug: fludarabine phosphate; Drug: melphalan; Drug: sirolimus; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: indium In 111 ibritumomab tiuxetan; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified May 2012
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Condition: Breast Cancer
Interventions: Drug: RAD001; Drug: Fulvestrant
Sponsors: University of Kentucky; University of Kentucky; Novartis
Recruiting - verified December 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Condition: Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Radiation: low dose total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine; Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma; Liver Cancer; Hepatoma
Interventions: Device: Bead Block microspheres; Other: Bead + Dox Arm
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Columbia University
Recruiting - verified March 2012
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide, fludarabine and rituximab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Celgene Corporation; Genentech
Recruiting - verified November 2011
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Conditions: Myelodysplastic Syndrome; Hodgkin's Lymphoma; Non-Hodgkin's Disease; Acute Leukemia; Multiple Myeloma
Interventions: Drug: Cyclophosphamide; Biological: rituximab; Drug: Methotrexate; Drug: Sirolimus; Drug: Cyclosporine; Drug: Doxorubicin hydrochloride; Drug: Etoposide; Drug: Fludarabine phosphate; Drug: Prednisone; Drug: Vincristine sulfate; Drug: Cytarabine; Drug: Tacrolimus; Biological: Alemtuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified June 2011
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Conditions: Inflammatory Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate; Drug: paclitaxel; Drug: doxorubicin hydrochloride; Drug: cyclophosphamide; Biological: filgrastim; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: etoposide; Drug: methotrexate; Drug: rasburicase; Drug: sirolimus; Drug: tacrolimus; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital
Recruiting - verified April 2008
Primary Breast Cancer Occurring Concomitant With Pregnancy

Conditions: Breast Cancer; Pregnancy
Interventions: Drug: 5-Fluorouracil; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

Conditions: Kidney Transplant; Kidney Transplantation; Renal Transplant
Interventions: Drug: ramipril; Drug: ramipril
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoblastic Lymphoma; Leukemia, Lymphoblastic, Acute
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Methotrexate; Drug: Vincristine; Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders

Condition: Sickle Cell Disease
Interventions: Biological: G-CSF; Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: Sirolimus; Procedure: Allogeneic bone marrow transplantation; Radiation: total-body irradiation; Drug: Levetiracetam
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Cyclophosphamide; Drug: Carmustine; Drug: Etoposide; Drug: Filgrastim; Drug: Antithymocyte globulin; Drug: Cyclosporine; Drug: Mycophenolate mofetil; Drug: rituximab
Sponsors: Stanford University; Stanford University
Recruiting - verified January 2012
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Conditions: Solid Tumor; Urethral Cancer
Interventions: Drug: Bortezomib; Drug: Gemcitabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

Conditions: Mantle Cell Lymphoma; Lymphoma
Interventions: Drug: Bortezomib; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Methotrexate; Drug: Cytarabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
ALL Adult Consortium Trial: Adult ALL Trial

Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Doxorubicin; Drug: Cytarabine; Drug: Methotrexate; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Methylprednisone; Drug: Hydrocortisone Sodium Succinate; Drug: Dexamethasone; Drug: 6-MP; Drug: PEG-Asparaginase; Drug: Imatinib; Drug: Etoposide; Procedure: Radiation Therapy; Drug: E. coli Asparaginase
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; Children's Hospital Boston
Recruiting - verified August 2011
LEA29Y (Belatacept) Emory Edmonton Protocol

Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Islet transplant; Drug: Belatacept; Drug: Basiliximab; Drug: Mycophenolate Mofetil
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

Conditions: Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Acute Myeloid Leukemia in Remission; Childhood Myelodysplastic Syndromes; de Novo Myelodysplastic Syndromes; Fanconi Anemia; Previously Treated Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Procedure: allogeneic bone marrow transplantation; Drug: mycophenolate mofetil; Drug: cyclosporine; Other: immunologic technique; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy

Condition: Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Genetic: RNA-based gene array studies; Genetic: Real time PCR gene expression studies; Genetic: Tissue-array immunohistochemical studies; Genetic: Immunoglobulin G Fc receptor genotypes determination
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Conditions: MUD Transplant; AlloPBSC; Congenital Immunodeficiencies; HLA Matched Transplant; BMT
Interventions: Drug: Busulfan; Drug: Campath-1 H; Drug: Sirolimus; Procedure: BMT; Procedure: Apheresis; Procedure: Total Body Irradiation; Procedure: GCSF Injections
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Precancerous Condition; Secondary Myelofibrosis
Interventions: Drug: Busulfan; Drug: Cytarabine; Drug: Fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; AML
Interventions: Drug: Cytarabine; Drug: Idarubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase 1b Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Condition: Lung Cancer
Intervention: Drug: RAD001
Sponsors: Emory University; Emory University
Recruiting - verified May 2012
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

Conditions: Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Paroxysmal Nocturnal Hemoglobinuria; Philadelphia Chromosome Negative Chronic Myelogenous Leukemia; Polycythemia Vera; Primary Myelofibrosis; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Radiation: total-body irradiation; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Cognitive/Functional Effects; Drug/Agent Toxicity by Tissue/Organ; Psychosocial Effects of Cancer and Its Treatment
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: methotrexate; Drug: sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Sirolimus for Autoimmune Disease of Blood Cells

Conditions: Autoimmune Pancytopenia; Autoimmune Lymphoproliferative Syndrome (ALPS); Evans Syndrome; Idiopathic Thrombocytopenic Purpura; Anemia, Hemolytic, Autoimmune; Autoimmune Neutropenia; Lupus Erythematosus, Systemic; Inflammatory Bowel Disease; Rheumatoid Arthritis
Intervention: Drug: sirolimus
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia
Recruiting - verified May 2012
Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL

Conditions: Acute Lymphoblastic Leukemia; Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Vincristine; Drug: Doxorubicin; Drug: Dexamethasone; Drug: Dasatinib; Drug: Methotrexate; Drug: Ara-C
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified November 2011
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders

Condition: Nonneoplastic Condition
Interventions: Drug: cyclophosphamide; Radiation: total-body irradiation; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: allogeneic bone marrow transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Combination Chemotherapy Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: melphalan; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011
TBI Dose De-escalation for Fanconi Anemia

Condition: Fanconi Anemia
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: anti-thymocyte globulin (ATG); Procedure: Total Body Irradiation; Procedure: Bone Marrow Transplantation; Drug: Mycophenolate Mofetil; Drug: Methylprednisolone
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Condition: Hodgkin's Lymphoma
Interventions: Drug: Adriamycin, Vinblastine, Vincristine, Bleomycin, Etoposide, Nitrogen Mustard (Cyclophosphamide), Prednisone; Procedure: Radiotherapy; Drug: Etoposide, Nitrogen Mustard (Cyclophosphamide) , Vincristine, Vinblastine, Adriamycin, Bleomycin, Prednisone
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified June 2011
PET Scan Combined With CT Scan in Predicting Response in Patients Undergoing Chemotherapy and Surgery for Soft Tissue Sarcoma

Condition: Sarcoma
Interventions: Biological: pegfilgrastim; Drug: doxorubicin hydrochloride; Drug: ifosfamide; Drug: pegylated liposomal doxorubicin hydrochloride; Procedure: conventional surgery; Radiation: fludeoxyglucose F 18
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: lyso-thermosensitive liposomal doxorubicin; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2007
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Drug: cyclophosphamide; Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: ex-vivo umbilical cord blood expansion; Procedure: double-unit umbilical cord blood transplantation; Procedure: biopsy; Other: immunologic technique; Other: diagnostic laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions: Hematologic Neoplasms; Neural Tube Defects; Myeloproliferative Disorders
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: Sirolimus
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

Conditions: Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelofibrosis; MDS; Refractory Anemia; Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Multiple Myeloma; Non-Hodgkin's Lymphoma; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

Conditions: Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

Conditions: Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: stem cell transplantation; Radiation: total-body irradiation; Drug: methylprednisolone; Drug: allopurinol; Drug: filgrastim
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: Etoposide phosphate; Drug: Melphalan; Drug: Carboplatin; Drug: Sodium thiosulfate; Drug: Filgrastim; Drug: Pegfilgrastim
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Rituximab&Methotrexate Chemotherapy w/BBBD & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL

Conditions: Brain and Central Nervous System Tumors; Lymphoma
Interventions: Drug: Rituxan; Drug: Carboplatin; Drug: Methotrexate; Drug: Sodium thiosulfate; Drug: Neupogen; Drug: Neulasta; Drug: Leucovorin
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Taxotere; Drug: Adriamycin/Cytoxan; Drug: docetaxol; Drug: doxorubicin
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Baylor College of Medicine
Recruiting - verified November 2011
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Intervention: Drug: ifosfamide and doxorubicin vs gemcitabine and docetaxel
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified February 2012
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Duke Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified April 2008
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; AIDS-related Diffuse Large Cell Lymphoma; AIDS-related Diffuse Mixed Cell Lymphoma; AIDS-related Diffuse Small Cleaved Cell Lymphoma; AIDS-related Immunoblastic Large Cell Lymphoma; AIDS-related Lymphoblastic Lymphoma; AIDS-related Peripheral/Systemic Lymphoma; AIDS-related Primary CNS Lymphoma; AIDS-related Small Noncleaved Cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Grade III Lymphomatoid Granulomatosis; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Essential Thrombocythemia; Extramedullary Plasmacytoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; HIV Infection; HIV-associated Hodgkin Lymphoma; Intraocular Lymphoma; Isolated Plasmacytoma of Bone; Juvenile Myelomonocytic Leukemia; Mast Cell Leukemia; Meningeal Chronic Myelogenous Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Central Nervous System Lymphoma; Primary Myelofibrosis; Primary Systemic Amyloidosis; Progressive Hairy Cell Leukemia, Initial Treatment; Prolymphocytic Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage 0 Chronic Lymphocytic Leukemia; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Hodgkin Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Childhood Small Noncleaved Cell Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Hodgkin Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Childhood Small Noncleaved Cell Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Hodgkin Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Childhood Small Noncleaved Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Hodgkin Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Childhood Small Noncleaved Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: total-body irradiation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia
Interventions: Biological: rituximab; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Myelodysplastic Syndromes; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; High Risk Metastatic Gestational Trophoblastic Tumor; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Childhood Rhabdomyosarcoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: pentostatin; Biological: therapeutic allogeneic lymphocytes; Drug: mycophenolate mofetil; Drug: cyclosporine
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum

Conditions: Carcinoma, Small Cell; Carcinoma, Non-small-cell Lung; Esophageal Neoplasms; Mesothelioma
Interventions: Drug: Depsipeptide; Drug: Flavopiridol (alvocidib)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Eosinophilic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Myelodysplastic Syndromes; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Childhood Anaplastic Large Cell Lymphoma; Stage I Childhood Large Cell Lymphoma; Stage I Childhood Lymphoblastic Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Childhood Anaplastic Large Cell Lymphoma; Stage II Childhood Large Cell Lymphoma; Stage II Childhood Lymphoblastic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Childhood Anaplastic Large Cell Lymphoma; Stage III Childhood Large Cell Lymphoma; Stage III Childhood Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Childhood Anaplastic Large Cell Lymphoma; Stage IV Childhood Large Cell Lymphoma; Stage IV Childhood Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies; Waldenstrom Macroglobulinemia
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: mycophenolate mofetil; Drug: tacrolimus; Procedure: bone marrow aspiration; Procedure: peripheral blood stem cell transplantation; Genetic: polymerase chain reaction; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
Recruiting - verified April 2012
Treating Patients With High-Grade Glioma With IA Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate

Conditions: Brain and Central Nervous System Tumors; Thrombocytopenia
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Etoposide phosphate; Drug: Etoposide; Drug: Sodium thiosulfate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

Conditions: Congenital Hemolytic Anemia; Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy; Drug: Alemtuzumab (Campath(Registered Trademark)); Drug: Sirolimus (Rapamune(Registered Trademark))
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 2011
Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Conditions: Adult Acute Lymphoblastic Leukemia in Remission; Blastic Phase Chronic Myelogenous Leukemia; Childhood Acute Lymphoblastic Leukemia in Remission; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Relapsing Chronic Myelogenous Leukemia
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: imatinib mesylate; Drug: dasatinib; Drug: nilotinib; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Drug: fludarabine phosphate; Procedure: peripheral blood stem cell transplantation; Biological: therapeutic allogeneic lymphocytes; Genetic: polymerase chain reaction; Other: flow cytometry; Genetic: fluorescence in situ hybridization; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Conditions: AIDS Related Lymphoma; HIV Infection
Interventions: Biological: Rituximab; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Burkitt Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: cyclophosphamide; Radiation: total-body irradiation; Drug: carmustine; Drug: etoposide; Drug: cytarabine; Drug: melphalan; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Drug: cyclosporine; Procedure: autologous hematopoietic stem cell transplantation; Biological: therapeutic autologous lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012